Novartis India (NSE:NOVARTIND) Net Loan

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:NOVARTIND Novartis India Ltd NSE:NOVARTIND
69 GF Score
Price ₹1,486.30
GF Value ₹1,040.75
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Novartis India Net Loan?

Net Loan only applies to banks and insurance companies.

NSE:NOVARTIND
69GF Score
Novartis India Ltd NSE:NOVARTIND
Net Loan is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Novartis India (NSE:NOVARTIND) Overvalued in 2026?

Based on GuruFocus' analysis, Novartis India stock appears to be overvalued. The current stock price of ₹1,486.30 is trading 42.8% above its estimated GF Value™ of ₹1,040.75. GuruFocus considers Novartis India to be Significantly Overvalued.

Key valuation signals for NSE:NOVARTIND:

  • Net Loan:
  • GF Value™: ₹1,040.75 vs. price of ₹1,486.30 (42.8% above fair value)
  • GF Score™: 69/100 with 3 warning signs

No single metric tells the full story. See the NSE:NOVARTIND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Novartis India Business Description

Other Exchanges 500672:India
Address Inspire BKC, Part of 601 & 701, Bandra Kurla Complex, Bandra (East), Mumbai, MH, IND, 400 051
Novartis India Ltd is an Indian-based pharmaceutical company. The company is engaged in the trading of Drugs and Pharmaceuticals. It derives revenue from operations in India. The company operates in a single business segment, namely Pharmaceutical Business. Its Pharmaceutical business focuses on Bone and Pain, Transplantation Immunology, and Neurosciences.
69GF Score

Get the complete analysis for NSE:NOVARTIND

Net Loan is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,486.30
Price
₹1,040.75
GF Value